Kornimate/medical-research-clean huggingface dataset:
laryngeal mask airway as a bridge for intubation of obese patients for sleeve gastrectomy

Conditions: Bariatric Surgery Candidate

Summary: ventilation, as well as intubation of a morbidly obese patient, is challenging and require special preparations and skilful hands, in this study laryngeal mask airway insertion is used as a bridge for intubation to facilitate ventilation as give enough time to anaesthetics and muscle relaxants to work on.

the ordinary pathway of intubating a morbidly obese patient for sleeve gastrectomy is bordered by the risk of difficult ventilation and intubation with the subsequent events of hypoxia and hypoventilation. when the patient is easy ventilated, it gives some sort of confidence and pleasure for the anaesthetist that the way of intubation will not be so hard. one problem here is the difficulty of ventilating a morbidly obese patient, in this study the investigators used laryngeal mask airway as a bridge before inserting the endotracheal tube

Eligibility criteria:
inclusion criteria: * morbid obese patient bmi\>40 * asa i, ii, iii * elective sleeve gastrectomy exclusion criteria: * oral cavity infection or pathological abnormalities * suspected or known abnormalities in supraglottic anatomy * patients planned for awake fiberoptic intubation
effects of whole-body vibration in the frail elderly

Conditions: Sarcopenia;; Osteoporosis

Summary: objective: to study the acute and chronic effects of whole-body vibration (wbv) exercises on the lower extremity blood flow, mobility function, balance, muscle strength, bone density, and general health status, and its feasibility as an intervention in frail elderly patients. design: randomized controlled trial. subjects: the frail older persons meeting the fried frailty criteria. interventions: all eligible subjects were randomly assigned to 4 groups: (1) wbv group: subjects received a whole-body vibration exercise alone; (2) progressive resistance training (prt) group: subjects received progressive resistance training; (3) wbv+ prt group: subjects received the whole-body vibration and progressive resistance training; (4) control group: subjects received no intervention/training. the periods of intervention are 12 weeks. main measures: the lower extremities blood flow (the diameters and red blood cell velocity of the common femoral artery), timed up and go test, 30-second chair stand test, five times sit to stand test, lower extremities muscle strength, balance function, balance confidence, bone density, and general health status was assessed at the beginning of the study, at instant, 12 weeks and 24 month after the intervention. study hypothesis: whole-body vibration exercise is a safe and effective method that can improve the lower extremity blood flow, mobility function, balance, muscle strength, bone density, and general health status in the frail elderly.


Eligibility criteria:
inclusion criteria: * ≥75 years old * fried frailty criteria * mini mental state examination score ≥18 exclusion criteria: * recent fractures (≤6 months) * gallbladder or kidney stones * malignancies * rheumatic arthritis * epilepsy * serious heart sicknesses or an implant, and bypass stent or cardiac pacemaker * any diseases to be associated with a life expectancy of less than 12 months

Keywords: whole-body vibration; frail elderly; blood flow; bone density mobility; balance; muscle strength; lower extremity; musculoskeletal system; health status; exercise; mechanical oscillation
investigation of the effectiveness of physiotherapy and rehabilitation after osteochondral allograft transplantation operation

Conditions: Cartilage Damage; Osteochondral Lesion; Allograft; Osteoarthritis of Knee

Summary: the aim of our study is to add to the literature the effect of the effectiveness of the physiotherapy and rehabilitation in the clinic, which will be applied to the patients after the osteochondral allograft transplantation operation, which is a current treatment approach applied after knee cartilage tissue damage, on the range of motion, functionality, pain and muscle strength of the patients during the recovery process. the clinical importance of our aim is that it will have the potential to guide health professionals in determining the appropriate treatment approach in order to reveal the best results that can be obtained due to the lack of many studies in the literature on the treatment of patients after osteochondral allograft surgery.


Eligibility criteria:
inclusion criteria: patients who underwent osteochondral allograft transplantation surgery participant's acceptance/desire to participate in the study exclusion criteria: patient participant's refusal/desire to participate in the study inability to perform exercises due to infection etc.

Keywords: physical therapy osteochondral allograft transplantation osteochondral lesion cartilage damage
efficacy of viome's precision nutrition program towards reducing hba1c

Conditions: Diabetes

Summary: this is a randomized, placebo-controlled trial that will test the efficacy of vpnp in reducing hba1c. participant recruitment will occur through direct-to-participant enrollment. no additional clinical sites will be used for recruitment.

this is a randomized, placebo-controlled trial that will test the efficacy of vpnp in reducing hba1c. participants with hba1c levels between 6.5-8.9% (inclusive) will be recruited and randomized into either the placebo or intervention group. the study duration for each participant will be approximately 90 days. at the beginning of the 90 days, the participant will complete online questionnaires, a blood draw, and a set of at-home sample collections for blood, stool, and saliva that will be sent back to viome. after the samples are analyzed, the participant will receive dietary recommendations and either personalized supplements or placebo supplements. the participant will follow the dietary recommendations and take the supplements for 90 days. at the end of the 90 days, the participant will once again complete online questionnaires, a blood draw, and a set of at-home sample collections for blood, stool, and saliva that will be sent back to viome for analysis.

Eligibility criteria:
inclusion criteria: * signed and dated informed consent form and medical release prior to any trial-specific procedures are performed * females and males aged 18 years or older * able to speak and read english * hba1c between 6.5-8.9% (inclusive), tested within the past 30 days * willing and able to visit a quest diagnostic patient service center (psc) * willing and able to follow the trial instructions and viome's precision nutrition program * willing and able to use a smartphone and viome app. exclusion criteria: * antibiotic use within one month of the gi test * gestation within previous 6 month * current (or previous) use of medications that increase insulin (sulfonylureas, such as glimepiride, glipizide, glyburide, etc.) * current (or previous) use of exogenous insulin (such as tresiba, lantus, toujeo, levemir, humalog, novolog, apidra, fiasp, etc.) * on a specific diet, such as ketogenic, for the purpose of reducing hba1c and/or weight within the previous month * taking diet pills * allergy to an ingredient in the mh capsule or stick pack * currently on an investigational product * significant surgery or medical procedure planned * diet or lifestyle change during the trial period, besides those appropriate for trial arm has followed viome nutritional recommendations (foods and/or supplements)

Keywords: health wellness nutrition vitamins supplements blood sugar diabetes fitness
study to evaluate the efficacy and safety of pf-06480605 in adult participants with moderate to severe crohn's disease

Conditions: Crohn Disease

Summary: this phase 2a, multicenter, randomized, double-blind, placebo-controlled study examines subcutaneous dose of pf-06480605 150 mg administered every 4 weeks in participants with moderate to severe active crohn's disease to characterize safety, efficacy, pharmacokinetics, and immunogenicity


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of ileocolonic or colonic cd with at least 3 months or longer prior to the baseline; * central read total ses-cd score of ≥7. for isolated ileal disease, ses-cd total score should be ≥4; * an average daily liquid/very soft sf ≥4 or daily ap score ≥2.0; * cdai between 220 and 450 inclusive; * must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for cd exclusion criteria: * diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, diverticular disease, uc, or clinical findings suggestive of uc; * presence of active (draining) fistulae or intra-abdominal or perineal abscesses; * strictures or stenosis with obstructive symptoms; * short bowel syndrome; * history of bowel perforation requiring surgical intervention within the past 12 months prior to baseline; * previous bowel surgery resulting in an existing stoma. participants who have a j-pouch are excluded, as a j-pouch can result in a stoma; * history of bowel surgery within 6 months prior to baseline.

Keywords: crohn disease, pf-06480605, ses-cd, cdai,
a prospective, randomized, double-masked, single center, clinical comparison of the use of systane ultra in the management of dry eyes in bilateral eyes

Conditions: Dry Eye

Summary: the primary objective of this study is to compare two post operative drop regimens for the management of dry eye and control of healing using fda-approved ophthalmic solutions.

this comparison will be made between bilateral eyes of the same patient following excimer laser ablation using the fda-approved ladarvision 4000 excimer laser system or the wavelight allegretto wave™ excimer laser system. post operative questionnaires regarding the use of the drops will be compared. tear osmolarity and tear breakup time will be evaluated using tear lab and oqas ii.

Eligibility criteria:
inclusion criteria: * subjects must be a suitable candidate for fda approved lasik. * subjects must have a stable refraction as documented by previous clinical records. * subjects who wear soft contact lenses must discontinue wear at least 3 days prior to preoperative exam or surgery. * subjects who wear gas permeable contact lenses must discontinue wear at least 3 weeks prior to preoperative exam or surgery. * subjects must be at least 18 years of age. * subjects must be willing and able to return for scheduled follow up examinations each day after surgery at the specified time. * subjects must sign and be given a copy of the written informed consent form. exclusion criteria: * subjects for whom either eyes do not meet all inclusion criteria and either eye meets any exclusion criteria. * subjects with clinically significant dry eye syndrome or clinically significant blepharitis in either eye. * subjects with clinically significant anterior segment pathology, including clinically significant cataracts, corneal scarring or neovascularization in either eye. * subjects who have undergone previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye. * subjects who have a history of herpes zoster or herpes simplex keratitis. * subjects on chronic systemic corticosteroid or other immunosuppressive therapy that may affect wound healing, any immunocompromised subjects, and subjects with clinically significant atopic disease, connective tissue disease, or uncontrolled diabetes. * subjects with a history of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative iop\>25 mm hg in either eye. * subjects with macular pathology in either eye. * subjects who are pregnant, lactating, or planning to be pregnant during the course of the study. * subjects with known sensitivity to planned study concomitant medications. * subjects participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation. * use of ocular drugs, other than study medications, during the study and within 30 days prior to study entry or any other ocular medication.

Keywords: dry eyes lasik laser vision correction
satisfaction and adherence to copd treatment

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the present study will explore the patients satisfaction to copd medical treatment (i.e. pharmacological and not pharmacological treatment) in a clinical real-world setting and how the satisfaction for medical treatment is related to clinical parameters, quality of life, illness perception and treatment adherence evolution. moreover health care resource consumption will be observed during the observation period.


Eligibility criteria:
inclusion criteria: 1. patients aged equal or more than 40 years 2. patients must have a documented diagnosis of chronic obstructive pulmonary disease (copd) 3. patients with no exacerbations in the last 3 months 4. patients requiring regular treatment according to gold guidelines, i.e.: undergoing stable pharmacological treatment for copd since at least 3 months 5. written informed consent to both participation in the study and privacy form 6. patients capable of discernment and able to read or write in italian language. exclusion criteria: 1. patients who are currently participating in a clinical trial on experimental drugs. 2. patients naïve to pharmacological treatment for copd 3. diagnosis of asthma copd overlap syndrome (acos)
salivary glycated albumin

Conditions: Diabetes Mellitus

Summary: (1) to determine whether the ratio of glycated albumin and total albumin in saliva is equivalent to blood and (2) to investigate whether the non-invasive smartalbu portable salivary sensor is as accurate as standard tests that measure glycosylated hemoglobin (hba1c).


Eligibility criteria:
inclusion criteria: * 123 individuals with type 1 or type 2 diabetes * 53 non diabetic controls * age: 18 to 80 * body mass index \>18.5kg / m2 exclusion criteria: * acute illness (within 7 days) - respiratory infection, fever above 38 °c, sinusitis infection, severe allergies. * individuals with known sickle cell, pregnancy, hemoglobinopathies, renal failure * subjects unable to give voluntary informed consent

Keywords: diabetes salivary glycated albumin hba1c
urinary proteomics analysis for sepsis and prognosis

Conditions: SIRS; Sepsis

Summary: as a noninvasive examination, urinary proteomics is a very useful tool to identify renal disease. the purpose of the present study was to find differential proteins among patient with sirs and sepsis(included survivors and non-survivors), and to screen potential biomarkers for the early diagnosis of sepsis and its prognosis. urinary proteins were identified by itraq labeling and lc-ms/ms. the bioinformatics analysis was performed with the mascot software and the international protein index (ipi) and the gene ontology (go) database and kegg pathway database. the differentially expressed proteins were verified by western blot by another sample collected from clinical.


Eligibility criteria:
inclusion criteria: * male and female aged 18 years old and over; * clinically confirmed infection; * fulfilled at least two criteria of systemic inflammatory response syndrome * (a) core temperature higher than 38 °c or lower than 36 °c * (b)respiratory rate above 20/min, or pco2 below 32 mmhg * (c) pulse rate above 90/min, and * (d) white blood cell count greater than 12,000/μl or lower than \< 4,000/μl or less than 10% of bands. exclusion criteria: * younger than 18 years of age; * acquired immunodeficiency syndrome; * reduced polymorphonuclear granulocyte counts (\< 500 μl-1); * died within 24h after admission into the icu, or refused to participate in the study, or declined treatment during the period of observation.

Keywords: proteomics,urinary,sepsis,prognosis
mri of neonate with hie before and during the moderate hypothermia

Conditions: Hypoxic-Ischemic Encephalopathy

Summary: moderate hypothermia has been demonstrated to be the effective treatment for neonates with hypoxic-ischemic encephalopathy (hie). however, few studies reveal the actual alterations in physiological parameters (i.e. brain temperature and cerebral blood flow) of neonates undergoing cooling, especially for hie lesions. therefore, this project aims to utilize the magnetic resonance imaging (mri), i.e. mr thermal imaging and phase contrast mri to measure the changes of these parameters before and during hypothermia; and then make comparisons with the routine nasopharyngeal and rectal temperature. all these would provide in vivo quantitative data for therapeutic evaluation and promote the optimization.

1. study objects 1.1 primary object to examine the changes of brain temperature and cerebral blood flow in neonates with hie before and during (i.e. cooling lasting for 24\~36 hr) selective brain cooling. 1.2 secondary object to compare the differences in temperature between brain (thalamus and hie lesions) and nasopharynx and rectum of hie neonates during the cooling. 2. methods prospective observational study; the mr thermal imaging and phase contrast mri will be used to estimate brain temperature and cerebral blood flow. neonates with hie who fulfilled the moderate hypothermia criteria will be recruited from the neonatal intensive care units. mr scans will be performed twice after informed parental consent. the first scan will be before the hypothermia and the second scan will be during the hypothermia. the first scan will be performed while the neonate is still in the intensive care unit. at the time of the second mr scan, the neonate is still in the intensive care unit, and the neonate in hypothermia group is receiving the brain selective cooling. sedation would be used if required in these babies.

Eligibility criteria:
inclusion criteria: * neonates in the neonatal intensive care unit who fulfill the hypothermia criteria for treating the hypoxic ischemic encephalopathy and who are scheduled to have an mri for evaluation of the extent of their injury. * parents, clinicians and physician consent to perform evaluation of mri before and during the hypothermia. exclusion criteria: * neonates too unstable to have mri exam, defined by being more than 40% oxygen on the ventilator. * hypothermia treatment interruption caused by potential factors. * neonates with central nervous system infection,intracranial hemorrhage and brain parenchyma lesions caused by trauma.
study to evaluate the immunogenicity and safety of an investigational influenza vaccine for the elderly

Conditions: Influenza

Summary: the objective of the study is to evaluate immunogenicity between different formulations of gsk biologicals' investigational vaccine gsk2186877a.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. specific attention should be given to the compliance potential of subjects with suspected or known drug or alcohol abuse. * a man or woman 65 years of age or older at the time of vaccination. * written informed consent obtained from the subject. * free of an acute aggravation of the health status as established by clinical evaluation before entering into the study. exclusion criteria: * any confirmed or suspected influenza illness within the last 6 months. * previous vaccination against influenza with any seasonal vaccine since december 2008. * planned administration of an influenza vaccine other than the study vaccines during the entire study period. * use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period. * administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. planned administration of a vaccine not foreseen by the study protocol up to visit 2. * administration of immunoglobulins and/or any blood products within the 3 months preceding the dose of study vaccine or planned administration during the study period. * chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose. for corticosteroids, this will mean prednisone \>= 0.5 mg/kg/day, or equivalent. inhaled and topical steroids are allowed. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * history of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s) including egg and chicken protein, included history of hypersensitivity to a previous dose of influenza vaccine. * acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * acute disease and/or fever at the time of enrolment. * fever is defined as temperature \>= 37.5°c on oral setting. * subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator. * any medical conditions in which intramuscular injections are contraindicated.

Keywords: influenza infection gsk bio's influenza vaccine gsk2186877a
surveillance of community-associated mrsa

Conditions: MRSA

Summary: the purpose of this study is to obtain information from patients diagnosed with a skin and soft tissue infection (also known as an abscess or 'boil' or 'rising') and determine whether or not mrsa is present in the child's different surface skin areas or nose. we also plan to compare how these infections look in the lab, by identifying in detail parts of the germ that caused the infection or is found on the skin/nose areas

patients come into the emergency department for skin and soft tissue infections, which could be caused by a germ not treatable with common medications. this germ is a bacterium called methicillin-resistant staphylococcus aureus (mrsa). mrsa is a bacterium that has become resistant to certain antibiotics. scientists and doctors are not sure what causes individuals to develop these infections, but it is believed to be related to the bacteria that might be on a patient's skin or in their nose. patients will be interviewed by someone from the research team to gather more details about possible risk factors related to mrsa infections. th interview is expected to last between 10-20 minutes. nasal (nose), axillary (armpit), throat, and around rectum swabs will be obtained by the research team as follows: culture swabs (similar to a large q-tip) will be inserted gently into the front half of each nostril (nare), under each arm, in the throat area, and around the perirectal area (surface skin around rectal opening) either before or after being seen by the emergency room physician. another culture swab of the patient's skin and soft tissue infection might be taken as part of their usual care for the child's condition or a swab culture will be taken from the infection site by research personnel. a 'culture' swab is a sterile q-tip like swab which is used to collect potential bacteria from the skin and nose, and then can be used in the laboratory to grow the bacteria collected.

Eligibility criteria:
inclusion criteria: * diagnosis of skin and soft tissue infections (abscesses and cellulitis) * patient aged \>6 months and \<21 years exclusion criteria: * currently on antibiotics * unimmunized patients * pertinent co-morbid conditions (immune deficiency, underlying cardiac, skin, gi disorder)